Navigation Links
CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007

ROCKVILLE, Md., April 4, 2007 -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies has been selected to present a poster abstract at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago Illinois, June 1-5. The poster session will take place from 8:00 am to 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of CytImmune will present the poster abstract entitled "Preliminary Results of a Phase I clinical trial of CYT-6091: A pegylated colloidal gold TNF nanomedicine.


"Acceptance to ASCO provides CytImmune the opportunity to present its research to the leading body of international oncology experts," said Dr. Lawrence Tamarkin, CEO of CytImmune Sciences. "For an emerging company, it's a chance interact with those in the field, advance science and demonstrate our role in the fight against cancer."


CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer pegylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities. To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby avoiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites. At 27 nanometers in size, CYT-6091 is able to exit the blood stream through leaky blood vessels and sequester in and around tumor sites with TNF binding to available receptors in this area. Preclinical studies indicate that CYT-6091 is then able to actively and passively target tumors, potentially delivering more drug to the site of disease with reduced side effects. The mechanism of targeting solid tumor s is independent of tumor type. Phase I clinical trials for CYT-6091 (Aurimune) began in May 2006 at the NCI Center for Cancer Research, Bethesda, MD.


Phase I preliminary trial data will be released according to ASCO's Abstract Policy, in which the information is confidential from the time of submission until the time the information is made publicly available at the ASCO Annual Meeting. The American Society of Clinical Oncology Annual Meeting is considered the premier educational and scientific event in the oncology community. In 2006, more than 29,000 attendees from around the world participated in the 42nd ASCO annual meeting in Atlanta, Georgia.


ABOUT CYTIMMUNE

CytImmune Sciences is a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies harnessing the unique properties of gold nanoparticles, known anti-cancer agents and biology of tumors. The platform technology allows for the targeted delivery of anti-caner therapies while avoiding update by healthy organs and tissues leading to improved efficacy, safety and patient outcomes. CytImmune hopes to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits.



Contact:
Alicia Moran
703-739-2424x110
'"/>




Related medicine technology :

1. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):